Slide 1: First Quarter 2023 Earnings Presentation
ANGIODYNAMICS First Quarter 2023 Earnings Presentation October 6, 2022 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q1 FY23 Highlights
Corporate Developments – Q1 FY23 Highlights • Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife • Q1 revenue growth of 5.9% Ø Med Tech up 29.6%; Med Device down 1.1% Ø $8.8 million in Auryon sales Ø 36.1% YOY growth in Mechanical Thrombectomy (Angi
Slide 4: Q1 FY23 Highlights
Q1 FY23 Highlights Financial Performance Q1 Revenue Contribution $ in thousands (except per share data) Med Tech Q1 FY23 Q1 FY22 Change Q1 FY22 Med Device Q1 FY23 Revenue $81,537 $76,971 5.9% Gross Margin 51.9% 52.1% (20 bps) 23% 28% Med Tech 63.2% 65.4% (220 bps) Med Device 47.5% 48.2% (70 bps) Net
Slide 5: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods Med Tech Q1 FY23 Auryon 50.0% Thrombus Management* 31.8% AngioVac 8.5% AlphaVac** N/A NanoKnife® Disposables 12.3% NanoKnife® Capital (37.2%) Med Device Q1 FY23 Solero® Microwave 6.1% BioSentry (13.4%) Core Peripheral 5.3% Venous (7.8%) Alatus and IsoLoc Balloo
Slide 6: Q1 FY23 Results (unaudited)
Q1 FY23 Results (unaudited) $ in thousands (except per share data) Q1 FY23 Q1 FY22 Change Revenue $81,537 $76,971 5.9% Med Tech $22,817 $17,607 29.6% Med Device $58,720 $59,364 (1.1%) United States $69,023 $64,464 7.1% International $12,514 $12,507 0.1% Net Loss ($13,004) ($6,972) ($6,032) Non-GAAP
Slide 7: Q1 FY23 Gross Margin Walk
Q1 FY23 Gross Margin Walk 80 Bps a i s19% coos) (100 Bps) a | (60 Bps) (80 Bps) 240 Bps Tight al Price/ Material Labor Freight Laser Production& Ql FY22 Mix Inflation Market Inflation Placements Operations FY23 >) angiodynamics
Slide 8: Q1 FY23 Cash Walk
Ca sh Ju n e1 D ra , 20 wo 22 $28.8 (in millions) nD ela y ed -Dr aw T e rm Lo a n $25.0 Op e ra ti n gC ash Ge ne rat i on Q1 FY23 Cash Walk $2.6 An nu al I n cen Is r ti v ael eC i In n om ov a p ti o $(10.2) nA u th o ri ty Pre pa ym en t $(4.4) Au ry o nL ase r Pu An rch nu ase al I n s $(2.2) s
Slide 9: FY23 Guidance
FY23 Guidance FY23 Guidance Reaffirmed Revenue $342 - $348 million Gross Margin 52.5% - 54.5% Med Tech 65% - 68% Med Device 45% - 48% Adjusted EPS $0.01 - $0.06 9
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 10
Slide 11: Reconciliation of GAAP to Non-GAAP Net Loss and EPS
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Net Loss and EPS EBITDA (in thousands, except per share data) (in thousands) (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certa